Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies

被引:2
|
作者
Fujisawa, Takuo [1 ]
Tsuta, Koji [2 ]
Yanagimoto, Hiroaki [3 ]
Yagi, Masao [1 ]
Suzuki, Kensuke [1 ]
Nishikawa, Kenji [4 ]
Takahashi, Masaru [4 ]
Okada, Hisatake [4 ]
Nakano, Yasushi [4 ]
Iwai, Hiroshi [1 ]
机构
[1] Kansai Med Univ, Dept Otolaryngol Head & Neck Surg, Osaka 5731010, Japan
[2] Kansai Med Univ, Dept Pathol & Lab Med, Osaka 5731010, Japan
[3] Kansai Med Univ, Dept Surg, Osaka 5731010, Japan
[4] Kon Minolta Inc, Corp R&D Headquarters, Bio Adv Technol Div, Bio Syst Dev Grp, Tokyo 1918511, Japan
关键词
programmed death ligand-1; digital immunostaining; ELISA; nCounter; EXPRESSION; PEMBROLIZUMAB;
D O I
10.3892/mco.2019.1801
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
One obstacle in diagnostic pathology is the harmonization of one drug-one diagnostic tests for programmed death ligand-1 (PD-L1). There are many challenges in accurate comparisons of diagnostic tests, such as differences in the titer of each antibody, detection system and dynamic range of visualization. Our previously developed digital immunostaining technique is highly sensitive and quantitative with the ability to quantify particles that bind in a one-to-one fashion with antibody in each cell. Determining the differences in the titer of each antibody with digital immunostaining may be beneficial for future harmonized analysis. To demonstrate the accuracy of digital immunostaining, the present study compared the number of particles with ELISA and nCounter data from five cell lines. NCI-H460 exhib-ited the highest level of PD-L1 protein, followed by A549, PC-3, NCI-H1299, and NCI-H446 cells. In addition, the PD-L1 mRNA values determined by nCounter corresponded with the order of the protein levels determined by ELISA. The present study revealed that digital immunostaining for PD-L1 was highly associated with ELISA and nCounter data. Among the four antibodies tested, the titer of all but SP142 coincided with ELISA and nCounter data. These results indicated that our digital immunostaining technique may be beneficial for future harmonized analysis.
引用
收藏
页码:391 / 396
页数:6
相关论文
共 50 条
  • [41] Evaluation of two immunohistochemical assays for PD-L1 expression.
    Anderson, Steven M.
    Zhang, Lei
    Brailey, Lisa
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] Comparison of PD-L1 immunohistochemical assays in head and neck carcinoma
    Jeong, J.
    Jo, U.
    Cho, K.
    Song, J. S.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S70 - S71
  • [43] Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer
    Hendry, Shona
    Byrne, David J.
    Wright, Gavin M.
    Young, Richard J.
    Sturrock, Sue
    Cooper, Wendy A.
    Fox, Stephen B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (03) : 367 - 376
  • [44] PD-L1 Immunostaining in Patients with Recurrent and Metastatic Gastrointestinal Stromal Tumors (GIST)
    Crystal, J. S.
    Makhoul, E.
    Cox, B.
    Balzer, B.
    Gangi, A.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S39 - S39
  • [45] Clinical performance and utilization of 3 PD-L1 immunohistochemical assays
    Anderson, Steven M.
    Horten, Bruce
    McCune, Bryan
    Paler, Ronald
    CANCER RESEARCH, 2017, 77
  • [46] PD-L1 immunohistochemical testing: A review with reference to cytology specimens
    Layfield, Lester J.
    Zhang, Tao
    Esebua, Magda
    DIAGNOSTIC CYTOPATHOLOGY, 2023, 51 (01) : 51 - 58
  • [47] PD-L1 expression in sarcomas: An immunohistochemical study and review of the literature
    Cunningham, Christopher R.
    Dodd, Leslie
    Esebua, Magda
    Layfield, Lester J.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2021, 55
  • [48] Quantitative comparison of PD-L1 immunohistochemical assays in hepatocellular carcinoma: The Blueprint-HCC study.
    Pinato, David James
    Mauri, Francesco A.
    Spina, Paolo
    Cain, Owen
    Siddique, Abdul
    Goldin, Robert D.
    Victor, Stephane
    Pizio, Corinna
    Akarca, Ayse
    Boldorini, Renzo
    Mazzucchelli, Luca
    Black, James M.
    Shetty, Shishir
    Marafioti, Teresa
    Sharma, Rohini
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [49] PD-1/PD-L1 Are Novel Therapeutic Targets for Mastocytosis
    Geeze, Mary
    Hatch, Ellen
    Martin, Cheyenne
    Perkins, Sherrie L.
    Hartmann, Karin
    Valent, Peter
    Gotlib, Jason
    Lidke, Diane
    George, Tracy I.
    MODERN PATHOLOGY, 2016, 29 : 346A - 346A
  • [50] INCB090244, A POTENT SMALL MOLECULE THAT INHIBITS THE PD-L1/PD-1 AXIS AND FUNCTIONS SIMILARLY TO PD-L1 ANTIBODIES
    Rios-Doria, Jonathan
    Volgina, Alla
    Gokhale, Prafulla
    Liu, Hao
    Stevens, Christina
    Zolotarjova, Nina
    DiMatteo, Darlise
    Kapilashrami, Kanishk
    Behshad, Elham
    Thekkat, Pramod
    Yang, Gengjie
    Hall, Leslie
    Kanellopoulou, Chrysi
    Rupar, Mark
    Maddage, Christopher
    Horsey, April
    Burke, Krista
    Yang, Yan-ou
    Covington, Maryanne
    Wang, Steve
    Liu, Phillip
    Wynn, Richard
    Reardon, David
    Koblish, Holly
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A247 - A247